Hot off the press! The 1Q11 OnBioVC Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!

The 1Q11 OnBioVC Trend Analysis tracked, in aggregate, 62 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling $1,176.7M. Compared to 1Q10 OnBioVC data, this investment activity represents a decrease in the number of quarter-over-quarter financings by 12 (62 v. 74) and a decrease in quarter-over-quarter total invested capital of $83.4M ($1,176.7M v. $1,260.1M).

Many thanks to our wonderful partners, please show them your support!

Apredica – Preclinical ADME Tox Contract Research
Colorado Bioscience Association – Advocacy. Representation. Service.
San Jose BioCenter – Giving emerging companies that Big Company Advantage…
Headwaters | MB – Independent middle market investment bank
Freestone Group – Integrated Solutions for Emerging Life Science
Lockton – Lifescience Industry Specific Insurance Needs
Regulus – A Full Spectrum of Regulatory Affairs and Quality Assurance Solutions
CID4 – Accelerating the Colorado bioscience ecosystem
BioBeers – Where Great Minds Drink Alike…

_________________________________________________________________________

Sign up [HERE] for FREE Subscriptions to ‘Pharmaceutical Executive’ and ‘Life Science Leader’ Magazines (and other journals too!)